Edwards Lifesciences Corporation (EW)
NYSE · Healthcare · Medical - Devices
Profile
Edwards Lifesciences Corporation
- Exchange
- NYSE
- Ticker
- EW
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- US
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Key facts
Edwards Lifesciences Corporation: key facts
- Edwards Lifesciences Corporation (NYSE: EW) is a Medical - Devices company in the Healthcare sector.
- In fiscal 2025, Edwards Lifesciences Corporation reported revenue of $6.1B and net income of $1.1B.
- Revenue grew 3.8% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $6.5B and net income was $1.0B.
MonkScore
Edwards Lifesciences Corporation's MonkScore
MonkScore
MonkScore range: 50–60
as of October 2026
Sector rank: 297 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth30–40
- Profitability50–60
- Quality20–30
- Market Conviction70–80
- Safety80–90
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Edwards Lifesciences Corporation's annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $6.5B | $6.1B | $5.4B | $5.0B | $5.4B | $5.2B |
| Gross profit | $5.1B | $4.7B | $4.3B | $4.0B | $4.2B | $4.0B |
| Operating income | $1.8B | $1.6B | $1.4B | $1.4B | $1.7B | $1.6B |
| Net income | $1.0B | $1.1B | $4.2B | $1.4B | $1.5B | $1.5B |
| Operating cash flow | $1.7B | $1.6B | $542.3M | $895.8M | $1.2B | $1.7B |
| Capital expenditure | -$286.7M | -$260.2M | -$252.4M | -$266.3M | -$264.8M | -$329.8M |
| Free cash flow | $1.4B | $1.3B | $289.9M | $629.5M | $953.4M | $1.4B |
| Total debt | $704.4M | $705.4M | $700.0M | $685.1M | $691.3M | $690.3M |
| Cash | $2.9B | $2.9B | $3.0B | $1.1B | $769.0M | $862.8M |
Revenue growth a year
- 1-year
- 11.5%
- 3-year
- 4.1%
- 4-year
- 3.8%
Compound growth between fiscal years.
Peers
Similar companies
- OrthoPediatrics Corp.NASDAQ:KIDSMonkScore range: 60–70
- LivaNova PLCNASDAQ:LIVNMonkScore range: 60–70
- Bruker CorporationNASDAQ:BRKRMonkScore range: 60–70
- Novocure LtdNASDAQ:NVCRMonkScore range: 60–70
- SI-BONE, Inc.NASDAQ:SIBNMonkScore range: 60–70
- Stryker CorporationNYSE:SYKMonkScore range: 70–80
- Inspire Medical Systems, Inc.NYSE:INSPMonkScore range: 70–80
- Globus Medical, Inc.NYSE:GMEDMonkScore range: 70–80
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.